WO1998045411A1 - Cell culture media for enhanced protein production - Google Patents

Cell culture media for enhanced protein production Download PDF

Info

Publication number
WO1998045411A1
WO1998045411A1 PCT/US1998/006800 US9806800W WO9845411A1 WO 1998045411 A1 WO1998045411 A1 WO 1998045411A1 US 9806800 W US9806800 W US 9806800W WO 9845411 A1 WO9845411 A1 WO 9845411A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
culture medium
amino acids
medium
cell culture
Prior art date
Application number
PCT/US1998/006800
Other languages
French (fr)
Inventor
Florence Chua
Steve Oh Kah Weng
Original Assignee
National University Of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Of Singapore filed Critical National University Of Singapore
Priority to JP54212698A priority Critical patent/JP2002501374A/en
Priority to CA 2286323 priority patent/CA2286323C/en
Priority to EP98915312A priority patent/EP0973867A4/en
Publication of WO1998045411A1 publication Critical patent/WO1998045411A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Definitions

  • This invention relates to cell culture media, which improves protein production, constrains cell growth and extends cell longevity jln vitro culture, and to methods for the production and use of such media.
  • the increasing demand for monoclonal antibodies (MABs) useful in research, diagnosis, therapy and purification purposes has created a need to optimize production techniques.
  • the prior art includes improved bioreactor designs and bioreactor operation to increase cell densities or the longevity of the culture by nutrient feedings .
  • Bioreactors have been operated in fed-batch, immobilized, perfusion and continuous modes. Alternate strategies, such as the use of temperature, media formulation, including the addition of mouse peritoneal factors, growth inhibitors, autocrine factors or cyclic mononucleotides and hyperstimulation by osmolarity stress, have been used to enhance protein production. These approaches have shown only marginal success .
  • CMOS basal cell culture media
  • RPMI 1640 DMEM (Dulbecco's modified Eagle's medium), Ham's F12 and DMEM/F12
  • DF DMEM/F12
  • Murakami showed that doubling total amino acids or glucose alone did not increase cell density but concurrent elevation of amino acids and glucose maximized the cellular growth by threefold.
  • Hyper-stimulation of monoclonal antibody production by high osmolarity stress in a eRDF medium is described in Chua et al . (1994) (2) and (1994) (3) .
  • the maximum IgG concentration achieved was about 300 ug/ml and 270 ug/ml for HG11 and TBC3 cells, respectively, at medium osmolarities about 350 to 400 mOsm. Further increase in osmolarity with NaCl caused a deterioration in antibody production.
  • the invention provides cell nutrient media which enhance protein production and prolong in vitro cell viability.
  • the method cell culture utilizing such media are an important aspect of the invention.
  • the media and the methods of the invention are applicable to the culture of cells of any type in bioreactors of all kinds.
  • Figure 2a-2d reflect the result of hollow fiber bioreactor experiments in which BTC-28101 was utilized.
  • Figure 2a represents levels of antibody produced.
  • Figure 2b sets forth medium pH data.
  • Figure 2c reports glucose utilization.
  • Figure 2d reprots cell viability.
  • Figure 3a growth of hybridoma 2HG11 in serum-free BTC-28101 and commercial media Hb and PFHM available from Gibco.
  • Figure 3b IgG concentration in serum-free BTC-28101 and commercial media Hb and PFHM available from Gibco.
  • Figure 4 growth of hybridomas 2HG11 and TBC3 in BTC-28102 and control DMEM/F12 media.
  • Figure 5 growth of CHO cells in BTC-28103 and control IMDM media.
  • IMDM refers to Iscove's Modified Dulbecco's Media.
  • Figure 6 presents a correlation of percent dry weight of amino acid in the media components with MAB production in ug/ml . The figure illustrates an unexpected increase in MAB concentration when the percent amino acid content in the media exceeds about 20%.
  • D/F refers to Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12, 1:1 Mixture.
  • Cell Culture Medium ny medium in which cells of any type may be cultured.
  • Bioreactor Any device in which cells may be cultured. Includes stationary flasks, spinner flasks and hollow fiber bioreactors.
  • Basal Medium cell culture medium that contains all of the ingredients essential to cell metabolism, e.g., amino acids, lipids, carbohydrates, vitamins and mineral salts.
  • RPMI , DMEM, Ham's 12 and RDF are examples of basal media.
  • Non-Essential Amino Acids Al, Asn, Asp, Gin, Gly, Ser.
  • the invention provides a method for improving protein production in cultures of protein producing cells.
  • the invention comprises culturing hybridomas antibody producing cells in a high osmolarity aqueous medium comprising a high concentration of amino acids, in particular the essential amino acids, and an energy source, such as glucose or sucrose.
  • the medium is substantially saturated at around 40°C with an amino acid or acids essential to the metabolism of the culture cells.
  • the medium of the invention contains 5.50 to 20 grams per liter of total or gross amino acids in solution or suspension and 5.50 to 20 grams per liter of a carbohydrate energy source, preferably glucose, in solution.
  • the gross amino acids comprise at least 20%, preferably, from about 25% to about 50% of the total dry weight of the medium components.
  • Cells may appropriately be adapted to the high osmolarity media of this invention by passaging.
  • the osmolarity of the medium is from 320 to 450.
  • Sodium chloride is the preferred osmolyte .
  • the media and the methods of the invention are useful in all forms of bioreactors.
  • the benefits of the invention are realized in static, batch, shaker flask, and spinner and hollow fiber bioreactor culture procedures .
  • Cells of all kinds may be cultured in any of the methods of the invention.
  • Culture of recombinant protein expression mammalian cells e.g., CHO cells
  • Many types of mammalian cells, which contain recombinant protein containing expression vectors are known. See, e.g., Acklin, C . , et al . (Recombinant human brain-derived neurotrophic factor (THuBHDNF) . Disulfide structure and characterization of BDNF expressed in CHO cells) Int.J.Pept. Protein Res. (1993) 11:548-52; Fukushima, K. , et al .
  • Medium BTC 28101 The dry powder form of Medium BTC-28101 was prepared as two separate components (A) and (B) as listed in Table I . The ingredients were milled to fine dry powder prior to use. To prepare the medium, Component (A) was dissolved in 90% by volume of pyrogen-free water. The mixture was warmed to around 40°C and stirred for one hour to fully dissolve the powder, and then cooled down to room temperature. Component (B) was added and stirred another hour to dissolve. pH was adjusted to 7.0 by addition of NaOH. Water was added to make up to the desired volume. The osmolarity of the medium was in the range of 330-335 mOsm/Kg. Table I - Composition of Medium BTC-28101 in mg/L
  • D-Ca pantothenate 1.240 Linoleic acid 0.020
  • composition of the medium BTC-28101 is
  • This example compares cell growth and monoclonal antibody production in two hybridoma cell lines 2HG11
  • the experiment was set up in shaker flasks with 100 ml media supplemented with 10% FBS (Fetal Bovine Serum) .
  • Inoculum cells were adapted and maintained by daily passaging at 2xl0 5 /ml with the respective fresh medium for at least a week, and the viability of each inoculum culture was above 90% before use.
  • Batch culture was started by inoculating at 2xl0 5 /ml into the respective medium. Samples were taken daily to follow the cell growth by trypan blue staining and hemocytometer counting. Monoclonal antibody concentration in the culture supernatant was determined by ELISA analysis. The effect on cell growth is shown in Fig. 1. Maximum concentration of Ig at the end of the cultures are summarized in Table II: Table II. Maximum Ig Concentration in the Cultures with BTC-28101 and Control DMEM/F12 Media
  • Hybridoma cell line TH12 (anti-theophylline) was cultured in either the BTC-28101 media of Example 1 or a DMEM formulation. Cells were inoculated into 100 ml of BTC-28101 or control medium DMEM at 2X10 5 /ml in 250 ml spinner flasks, both media were supplemented with 10% FBS. Similar procedure as stated in Example 2 was followed for preparing the inoculum cultures, and for monitoring the batch. TH12 produced higher concentrations of antibody in BTC-28101 than in the formulation of DMEM. As Table III shows, cell numbers and cell viability were also higher in 28101.
  • Table IV demonstrates enhanced Ig production and specific antibody titer when BTC-28101 is used.
  • Ig concentrations determined by precipitating each sample with saturated ammonium sulfate and reading optical densities at 280 nm.
  • Hybridoma cell line DI16 (anti-Dirofilaria immitis' was cultured in either the BTC-28101 or DMEM. DI16 produced higher concentrations of antibody in BTC-28101 than in the in-house formulation of DMEM. Table V shows that cell numbers and cell viability were also higher in BTC-28101.
  • Table VI reports comparative Ig titers and concentration.
  • Ig titers determined by titrating samples in a mouse Ig capture ELISA.
  • Hybridoma cell line NP11 (anti-N-acetylprocainamide) was cultured in either BTC-28101 or DMEM. This cell line was slightly slower than the other cell lines to respond to BTC-28101 with enhanced levels of antibody production; variations for different cell lines are not surprising. It is significant that the BTC-28101 culture produced substantial levels of antibody when cultures in DMEM were no longer viable. The ability to keep cultures producing for longer periods of time is a significant advantage of BTC-28101. See Table VII.
  • EXAMPLE 8 Spinner Flask Experiments with BTC 28101 Medium Anti-theophylline hybridoma cells were inoculated into 250 ml of Difco's preparation of BTC 28101 or DMEM at 2 x 10 5 cells/ml in 500 ml spinner flasks. Both media were supplemented with 10% FBS, 2% L-glutamine, and 1% pen-strep. Five ml samples were collected from each flask on the days indicated. Cell viability was determined each day samples were collected, and antibody concentrations were determined for all samples by radial immunodiffusion (RID) after all had been collected. Until that time, the samples (with cell material removed by centrifugation) were stored at -20°C. Antibody concentrations, as determined by RID, and cell viabilities are described in Table IX:
  • the cell line utilized produced 1 mg/ml under conditions described. Specifically, the spinner flasks did not provide ideal culture conditions. Once the experiment was set up, the medium was never replaced or replenished. Consequently, metabolites and dead cells continued to accumulate.
  • EXAMPLE 9 Anti-theophylline hybridoma cells were inoculated into 100 ml of Difco' s preparation of BTC 28101 or in- house medium (DMEM) at 2 x 10 5 cells/ml in 250 ml spinner flasks. All other parameters were as described in Example 8. Antibody concentrations, as determined by RID, and cell viabilities are described in Table X:
  • Example 9 the culture volume in Example 9 was one- half that in Example 8. Consequently, nutrients may have depleted more quickly and metabolites or other materials accumulated in inhibitory concentrations more rapidly.
  • Hybridoma 2HG11 has been adapted to serum-free conditions in the respective media. All media were supplemented with insulin, transferrin, ethanolamine and selenite. Cells were inoculated into 100 ml of BTC-28101 or control media at 2xl0 5 /ml in 250 ml shaker flasks.
  • Medium BTC-28101 was further enhanced to formulate Medium-28102.
  • Component (C) was prepared according to the composition in Table XI and milled to dry fine powder. The powder was sterilized by gamma-irradiation and added to 100 ml of BTC-28101, constituting the Medium BTC-
  • Osmolarity of the medium was around 400 mOsm/Kg.
  • Cystine is utilized in lieu of cysteine which is toxic to cells at high concentration.
  • composition of medium BTC-28102 is: Glucose 10.269 g/1
  • Inoculum cells were adapted to Medium BTC-28101 following the protocol stated in Example 2 and inoculated at 2xl0 5 /ml when starting the shaker batch, along with the control cells in 100 ml of DMEM/F12 medium. The effects on cell growth are shown in Fig. 4. Maximum concentration of Ig in the culture are summarized in Table XII.
  • BTC-28103 was prepared as in BTC- 28101 but the buffer contents of HEPES and NaHCO were increased to 8330 mg/1 and 2650 mg/1, respectively. As a result, osmolarity of the medium was increased to 360 mOsm/Kg.
  • CHO (Chinese Hamster Ovary) cells were adapted to grow in suspension and cultured in 100 ml of BTC-28103 and the control IMDM in shaker flasks, both supplied with 10% FBS, thymidine and hypoxanthine . Growth of the cultures was followed daily by hemocytometer counting and presented in Fig. 5.
  • the media of the invention is useful to culture protein expressing cell lines in the various forms of available bioreactors.
  • media of this invention may be used as the intracapillary medium in hollow fiber bioreactor culture of recombinant protein expressing CHO cells.
  • Table XIII indicates the composition of the commercially available media RPMI , D/F and eRDF and of the 28101 (Example 1) and 28102 (Example 11) media of the invention. Table XIII
  • a novel cell culture media which improves protein production by cells of all types including mammalian cells which express recombinant protein vectors has been disclosed.
  • the invention will substantially enhance the cost effectiveness of cell culture procedures generally including the production of monoclonal antibodies.

Abstract

A cell culture medium is provided which constrains cell growth and enhances antibody production. The high glucose medium of the invention is preferably saturated at 40 °C with essential amino acids.

Description

CELL CULTXJRE MEDIA FOR ENHANCED PROTEIN PRODUCTION
This application is a continuation of United States application Serial No. 08/833,500 filed 07 April 1997.
FIELD OF THE INVENTION This invention relates to cell culture media, which improves protein production, constrains cell growth and extends cell longevity jln vitro culture, and to methods for the production and use of such media.
BACKGROUND OF THE INVENTION The increasing demand for monoclonal antibodies (MABs) useful in research, diagnosis, therapy and purification purposes has created a need to optimize production techniques. The prior art includes improved bioreactor designs and bioreactor operation to increase cell densities or the longevity of the culture by nutrient feedings .
Bioreactors have been operated in fed-batch, immobilized, perfusion and continuous modes. Alternate strategies, such as the use of temperature, media formulation, including the addition of mouse peritoneal factors, growth inhibitors, autocrine factors or cyclic mononucleotides and hyperstimulation by osmolarity stress, have been used to enhance protein production. These approaches have shown only marginal success .
Commonly used basal cell culture media are RPMI 1640, DMEM (Dulbecco's modified Eagle's medium), Ham's F12 and DMEM/F12 (DF) . Murakami (1989) (l)1 describes a modified medium, eRDF, prepared from RDF (RPMI :DMEM: F12=2:l:l) by enrichment with amino acids, glucose and vitamins. Murakami showed that doubling total amino acids or glucose alone did not increase cell density but concurrent elevation of amino acids and glucose maximized the cellular growth by threefold. Hyper-stimulation of monoclonal antibody production by high osmolarity stress in a eRDF medium is described in Chua et al . (1994) (2) and (1994) (3) . However, the maximum IgG concentration achieved was about 300 ug/ml and 270 ug/ml for HG11 and TBC3 cells, respectively, at medium osmolarities about 350 to 400 mOsm. Further increase in osmolarity with NaCl caused a deterioration in antibody production. Oh, et al . (1995) (4) reports that hybridomas increased metabolic activities and amino acids uptake via the Na+ dependent symports to compensate for the osmotically elevated external environment.
Oh, et al . (1996) (5) describes the application of flow cytometry in examining the relationships between total cellular monoclonal antibody content, cell size, and cell cycle distribution of hybridomas subjected to environmental stress.
A bibliography precedes the claims SUMMARY OF THE INVENTION The invention provides cell nutrient media which enhance protein production and prolong in vitro cell viability. The method cell culture utilizing such media are an important aspect of the invention.
The media and the methods of the invention are applicable to the culture of cells of any type in bioreactors of all kinds.
DETAILED DESCRIPTION OF THE DRAWINGS Figure 1—growth of hybridomas 2HG11 and TBC3 in
BTC-28101 and control DMEM/F12 media.
Figure 2a-2d reflect the result of hollow fiber bioreactor experiments in which BTC-28101 was utilized. Figure 2a represents levels of antibody produced. Figure 2b sets forth medium pH data. Figure 2c reports glucose utilization. Figure 2d reprots cell viability.
Figure 3a—growth of hybridoma 2HG11 in serum-free BTC-28101 and commercial media Hb and PFHM available from Gibco. Figure 3b—IgG concentration in serum-free BTC-28101 and commercial media Hb and PFHM available from Gibco. Figure 4—growth of hybridomas 2HG11 and TBC3 in BTC-28102 and control DMEM/F12 media.
Figure 5—growth of CHO cells in BTC-28103 and control IMDM media. IMDM refers to Iscove's Modified Dulbecco's Media. Figure 6 presents a correlation of percent dry weight of amino acid in the media components with MAB production in ug/ml . The figure illustrates an unexpected increase in MAB concentration when the percent amino acid content in the media exceeds about 20%. In the Figure D/F refers to Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12, 1:1 Mixture.
DEFINITIONS Cell Culture Medium— ny medium in which cells of any type may be cultured.
Bioreactor—Any device in which cells may be cultured. Includes stationary flasks, spinner flasks and hollow fiber bioreactors.
Basal Medium— cell culture medium that contains all of the ingredients essential to cell metabolism, e.g., amino acids, lipids, carbohydrates, vitamins and mineral salts. RPMI , DMEM, Ham's 12 and RDF are examples of basal media.
Essential Amino Acids— rg, Cys, Gin, His, Pro, lie, Leu, Lys, Met, Phe, Thr, Trp, Tyr and Val .
Non-Essential Amino Acids—Ala, Asn, Asp, Gin, Gly, Ser.
DETAILED DESCRIPTION OF THE INVENTION The invention provides a method for improving protein production in cultures of protein producing cells. In particular, the invention comprises culturing hybridomas antibody producing cells in a high osmolarity aqueous medium comprising a high concentration of amino acids, in particular the essential amino acids, and an energy source, such as glucose or sucrose. The medium is substantially saturated at around 40°C with an amino acid or acids essential to the metabolism of the culture cells. The medium of the invention contains 5.50 to 20 grams per liter of total or gross amino acids in solution or suspension and 5.50 to 20 grams per liter of a carbohydrate energy source, preferably glucose, in solution. The gross amino acids comprise at least 20%, preferably, from about 25% to about 50% of the total dry weight of the medium components. Cells may appropriately be adapted to the high osmolarity media of this invention by passaging. The osmolarity of the medium is from 320 to 450.
Sodium chloride is the preferred osmolyte .
The media and the methods of the invention are useful in all forms of bioreactors. The benefits of the invention are realized in static, batch, shaker flask, and spinner and hollow fiber bioreactor culture procedures .
Cells of all kinds may be cultured in any of the methods of the invention. Culture of recombinant protein expression mammalian cells, e.g., CHO cells, is an important aspect of the invention. Many types of mammalian cells, which contain recombinant protein containing expression vectors are known. See, e.g., Acklin, C . , et al . (Recombinant human brain-derived neurotrophic factor (THuBHDNF) . Disulfide structure and characterization of BDNF expressed in CHO cells) Int.J.Pept. Protein Res. (1993) 11:548-52; Fukushima, K. , et al . , (N-linked sugar chain structure of recombinant human lymphotoxin produced by CHO cells; the functional role of carbohydrate as to its lectin-like character and clearance velocity) ABB (1993) 3_04_: 144-53 ; Hayakawa, T., et al . (In vivo biological activities of recombinant human erythropoietin analogs produced by CHO cells, BHK cells and C127 cells) Bioloσicals (1992) 20:253-7: Israel, D.I., et al . (Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells) GF (1992) 2:139-50; Langley, K.E., et al . (Purification and characterization of soluble forms of human and rat stem cell factor recombinantly expressed by Escherichia coli and by Chinese hamster ovary cells) ABB (1992) 295 : 21-8 ; Lu, H.S., et al . (Post-translational processing of membrane-associated recombinant human stem cell factor expressed in Chinese hamster ovary cells) 298:150-8; Malik, N., et al . , (Amplification and expression of heterologous oncostatin M in Chinese hamster ovary cells) DNA Cell Biol . (1992) 11:453-9; Nagao, M. , et al . (Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor) Biochem. Biophys . Res. Commun. (1992) 188 :888-97; Rice, K.G., et al . (Quantitative mapping of the n-linked sialyloligosaccharides of recombinant erythropoietin; combination of direct high- performance anion-exchange chromatography and 2- aminopyridine derivatization) Anal. Biochem. (1992) 206:278-87; Schmelzer, C.H., et al . (Purification and partial characterization of recombinant human differentiation-stimulating factor) Protein Expr. Purif. (1990) 1:54-62; Schmelzer, C.H., et al . (Biochemical characterization of human nerve growth factor) J. Neurochem. (1992) .59:1675-83; Sima, N. , et al . (Tumor cytotoxic factor/hepatocyte growth factor from human fibroblasts; cloning of its cDNA, purification and characterization of recombinant protein) Biochem. Biophys. Res. Commun. (1992) 180:1151-8; Sun, X.J., et al . (Expression and function of IRS-1 in insulin signal transmission) J. Biol . Chem. (1992) 212:22662-72; Suzuki, A., et al . (Biochemical properties of amphibian bone morphogenetic protein-4 expressed in CHO cells) BJ (1993) 291:413-7; Tressel, T.J., et al . (Purification and characterization of human recombinant insulin-like growth factor binding protein 3 expressed in Chinese hamster ovary cells) Biochem. Biophys. Res. Commun. (1991) 128:625-33. See also Lucas, B.K., et al . (High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector) (1996) Nucleic Acids Res. 24:1774-9. EXAMPLE 1 Medium BTC 28101 The dry powder form of Medium BTC-28101 was prepared as two separate components (A) and (B) as listed in Table I . The ingredients were milled to fine dry powder prior to use. To prepare the medium, Component (A) was dissolved in 90% by volume of pyrogen-free water. The mixture was warmed to around 40°C and stirred for one hour to fully dissolve the powder, and then cooled down to room temperature. Component (B) was added and stirred another hour to dissolve. pH was adjusted to 7.0 by addition of NaOH. Water was added to make up to the desired volume. The osmolarity of the medium was in the range of 330-335 mOsm/Kg. Table I - Composition of Medium BTC-28101 in mg/L
Component (A)
Amino Acids
Alanine 13.4
Arginine.HCl 1,162.9 Asparagine.H20 189.2
Aspartic acid 80.0
Cystine.2HCl 105.4
Cysteine.HCl.H20 105.4
Gluta ic acid 79.4 Glutamine 1,997.2
Glycine 85.6
Histidine.HCl.H20 150.9
Hydroxyproline 63.0
Isoleucine 314.8 Leucine 330.6
Lysine.HCl 394.6
Methionine 98.4
Phenylalanine 148.6 Proline 110.6
Serine 170.2
Threonine 221.6
Tryptophan 36.8
Tyrosine 174.0
Valine 218.0
Component (B)
Mineral Salts Carbohydrates and derivatives
CaCl2 (anh) 82.1 D-glucose 6 ,846.0
CuS04.5H20 0.00075 Na Pyruvate 110.0
FeS04.7H20 0.220
KC1 372.8 Nucleic acid derivatives
MgS04 (anh.) 52.4 Thymidine 5.7
NaCl 6,136.2 Hypoxanthine 1.0
Na2HP04 (anh.) 484.1
ZnS04.7H20 0.230
Lipids and derivatives
Vitamins Choline bitartrate 55.7
Biotin 0.102 i-inositol 104.5
D-Ca pantothenate 1.240 Linoleic acid 0.020
Folic acid 8.800 Lipoic acid 0.050
Putrescine .2HC1 0.040
Niacinamide 1.510 Thiol compound
Para-aminobenzoic Glutathione acid 0.510 (reduced) 0.490
Pyridoxine . HC1 0.520
Pyridoxal .HC1 1.000 Buffers
Riboflavin 0.210 HEPES 3,570.0
Thiamine. HC1 1.585 NaHC03 1, 130.0
Vitamin B12 0.342 pH indicator
Phenol red 6.0
The composition of the medium BTC-28101 is
Glucose (mg/1) 6.846 Amino acids (mg/1) 6.251 Amino acids (%d.w.*) 24.8 *dry weight of media ingredients EXAMPLE 2
Effect of Medium BTC-28101 on IgG Production in Hybridomas in Shaker Flask Culture
This example compares cell growth and monoclonal antibody production in two hybridoma cell lines 2HG11
(antihuman chorionic gonadotropin) and TBC3 (antihuman
IgG) in the serum supplemented in the BTC-28101 medium of Example 1 versus DMEM/F12 (Dulbecco's modified Eagle's medium: Ham's F12=l:l).
The experiment was set up in shaker flasks with 100 ml media supplemented with 10% FBS (Fetal Bovine Serum) . Inoculum cells were adapted and maintained by daily passaging at 2xl05/ml with the respective fresh medium for at least a week, and the viability of each inoculum culture was above 90% before use. Batch culture was started by inoculating at 2xl05/ml into the respective medium. Samples were taken daily to follow the cell growth by trypan blue staining and hemocytometer counting. Monoclonal antibody concentration in the culture supernatant was determined by ELISA analysis. The effect on cell growth is shown in Fig. 1. Maximum concentration of Ig at the end of the cultures are summarized in Table II: Table II. Maximum Ig Concentration in the Cultures with BTC-28101 and Control DMEM/F12 Media
Cell Line Max Ig Concentration (ug/ml) DMEM/F12 BTC-28101
2HG11 50 270
TBC3 84 450
EXAMPLE 3
Hybridoma cell line TH12 (anti-theophylline) was cultured in either the BTC-28101 media of Example 1 or a DMEM formulation. Cells were inoculated into 100 ml of BTC-28101 or control medium DMEM at 2X105/ml in 250 ml spinner flasks, both media were supplemented with 10% FBS. Similar procedure as stated in Example 2 was followed for preparing the inoculum cultures, and for monitoring the batch. TH12 produced higher concentrations of antibody in BTC-28101 than in the formulation of DMEM. As Table III shows, cell numbers and cell viability were also higher in 28101.
Table I I I
TH12 Batch Culture: Cell Counts and Viabilities
Figure imgf000014_0001
Viabilities in both media were <5%.
Total media volumes collected for analyses.
Table IV demonstrates enhanced Ig production and specific antibody titer when BTC-28101 is used. Table IV
TH12 Batch Culture: Ig Concentrations and Specific Antibody Titers.
Figure imgf000015_0001
1 Ig concentrations determined by precipitating each sample with saturated ammonium sulfate and reading optical densities at 280 nm.
2 Specific antibody titers determined in an indirect ELISA with theophylline-BSA on the solid phase.
EXAMPLE 4 Hybridoma cell line DI16 (anti-Dirofilaria immitis' was cultured in either the BTC-28101 or DMEM. DI16 produced higher concentrations of antibody in BTC-28101 than in the in-house formulation of DMEM. Table V shows that cell numbers and cell viability were also higher in BTC-28101.
Table V DI16 Batch Culture: Cell Counts and Viabilities
Figure imgf000016_0001
Table VI reports comparative Ig titers and concentration.
Table VI DI16 Batch Culture: Ig Titers and Concentrations
Figure imgf000017_0001
1 Ig titers determined by titrating samples in a mouse Ig capture ELISA.
2 Ig concentrations determined by precipitating each sample with saturated ammonium sulfate and reading optical densities at 280 nm; mg/ml=O.D. 280 x dilution factor ÷ 1.41 extinction coefficient.
EXAMPLE 5 Hybridoma cell line NP11 (anti-N-acetylprocainamide) was cultured in either BTC-28101 or DMEM. This cell line was slightly slower than the other cell lines to respond to BTC-28101 with enhanced levels of antibody production; variations for different cell lines are not surprising. It is significant that the BTC-28101 culture produced substantial levels of antibody when cultures in DMEM were no longer viable. The ability to keep cultures producing for longer periods of time is a significant advantage of BTC-28101. See Table VII.
Table VII
NP11 Batch Culture: Cell Counts and Viabilities
Figure imgf000018_0001
EXAMPLE 6
Effect of BTC-28101 on IσG Production in Hollow Fiber Culture
Performance of the hybridoma in a "mini" hollow fiber bioreactor (UniSyn Technologies, Inc . ' s "Mini
Mouse" bioreactor) supplied with FBS supplemented BTC-
28101 was compared with the control FBS supplemented DMEM. The results are shown in Table VIII. Comparable levels of antibody were produced by this hybridoma in the control DMEM and in BTC-28101. However, the control culture was terminated after day 13 when viability was <10%. In contrary, the cells in BTC-28101 remained highly viable, and the culture was terminated only because of shortage of medium supply.
Table VIII. Comparison of Ig Titer of Hollow Fiber Culture in BTC-28101 and Control DMEM Media
Time (day) BTC-28101 DMEM
2 1:6,400 1:51,200
5 1:102,400 1:204, 800 7 1:204,800 1:204, 800 9 1:204,800 1:102,400 12 1:204,800 1:102,400 14 1:204,800 16 1:102,400 19 1:51,200 EXAMPLE 7 Hollow Fiber Bioreactors—28101 Medium This hollow fiber bioreactor experiment involved a particular cell line which normally produces a few hundred ug/ml of MAB in conventional method. Fig. 2a indicates that this cell line performed substantially better in BTC-28101. Data for pH of the medium (Fig. 2b), glucose utilization (Fig. 2c), and cell viability (Fig. 2d) are presented. Cells growing in BTC- 28101 in hollow fiber bioreactors do not appear to utilize glucose from the medium at the rate normally seen with conventional media. Monitoring of glucose utilization is a standard means of monitoring the progress of cells in hollow fiber bioreactors—the higher the level of glucose utilization, the better the cells are growing .
EXAMPLE 8 Spinner Flask Experiments with BTC 28101 Medium Anti-theophylline hybridoma cells were inoculated into 250 ml of Difco's preparation of BTC 28101 or DMEM at 2 x 105 cells/ml in 500 ml spinner flasks. Both media were supplemented with 10% FBS, 2% L-glutamine, and 1% pen-strep. Five ml samples were collected from each flask on the days indicated. Cell viability was determined each day samples were collected, and antibody concentrations were determined for all samples by radial immunodiffusion (RID) after all had been collected. Until that time, the samples (with cell material removed by centrifugation) were stored at -20°C. Antibody concentrations, as determined by RID, and cell viabilities are described in Table IX:
Table IX
Day 0 = 12/30/96 ucr/ml Ab C Cell Viability
Day DMEM Difco DMEM Difco
0 <125* <125 95% 95%
1 <125 <125 94% 95%
3 <125 <125 95% 95%
4 <125 <125 58% 86%
7 <125 176 0 27%
8 562 0 21%
9 473 0 23%
14 1, 035 0 19%
*The lowest concentration RID standard used was 125 ug/ml.
It is significant that the cell line utilized produced 1 mg/ml under conditions described. Specifically, the spinner flasks did not provide ideal culture conditions. Once the experiment was set up, the medium was never replaced or replenished. Consequently, metabolites and dead cells continued to accumulate.
EXAMPLE 9 Anti-theophylline hybridoma cells were inoculated into 100 ml of Difco' s preparation of BTC 28101 or in- house medium (DMEM) at 2 x 105 cells/ml in 250 ml spinner flasks. All other parameters were as described in Example 8. Antibody concentrations, as determined by RID, and cell viabilities are described in Table X:
Table X Day 0 = 1/18/97 ug/ml 7Ab Cell Viability
Day DMEM Difco DMEM Difco
1 <125* <125 95% 99%
3 <125 156 87% 99%
4 <125 209 49% 74%
5 <125 436 16% 65%
6 <125 417 9% 39%
7 <125 417 0 14%
9 400 0 10%
*The lowest concentration RID standard used was 125 ug/ml .
Note that the culture volume in Example 9 was one- half that in Example 8. Consequently, nutrients may have depleted more quickly and metabolites or other materials accumulated in inhibitory concentrations more rapidly.
EXAMPLE 10 BTC-28101 on IαG Production in Serum-Free Culture This example compares cell growth and monoclonal antibody production in a hybridoma cell line (2HG11) in serum-free BTC-28101 and other commercially available serum-free media available from Gibco.
Hybridoma 2HG11 has been adapted to serum-free conditions in the respective media. All media were supplemented with insulin, transferrin, ethanolamine and selenite. Cells were inoculated into 100 ml of BTC-28101 or control media at 2xl05/ml in 250 ml shaker flasks.
The results on growth and IgG production are shown in
Figs. 3a and 3b.
EXAMPLE 11 Preparation and Use of BTC-28102 to Culture Hybridomas
Nutrient contents of the Medium BTC-28101 was further enhanced to formulate Medium-28102. To prepare this medium, Component (C) was prepared according to the composition in Table XI and milled to dry fine powder. The powder was sterilized by gamma-irradiation and added to 100 ml of BTC-28101, constituting the Medium BTC-
28102. Osmolarity of the medium was around 400 mOsm/Kg.
Table XI: Composition of Supplement to
Medium BTC-28101 to Make Up BTC-28102
Component (C) in mg
Alanine 2.0
Arginine .HC1 174.4
Asparagine . H20 28.4
Aspartic acid 12.0
Cystine.2HCl 31.6
Glutamic acid 11.9
Glutamine 299.6
Glycine 12.8
Histidine.HCl.H20 22.6
Hydroxyproline 9.5
Isoleucine 47.2
Leucine 49.6
Lysine .HC1 59.2
Methionine 14.8
Phenylalanine 22.3
Proline 16.6
Serine 25.5 Threonine 33.2
Tryptophan 5.5
Tyrosine 26.1
Valine 32.7 Glucose 3,423
Cystine is utilized in lieu of cysteine which is toxic to cells at high concentration.
The composition of medium BTC-28102 is: Glucose 10.269 g/1
Amino Acids 15.628 g/1
Amino Acids ( % d.w. of media ingredients) 41.1
Inoculum cells were adapted to Medium BTC-28101 following the protocol stated in Example 2 and inoculated at 2xl05/ml when starting the shaker batch, along with the control cells in 100 ml of DMEM/F12 medium. The effects on cell growth are shown in Fig. 4. Maximum concentration of Ig in the culture are summarized in Table XII.
Table XII: Maximum Ig Concentration in the cultures with BTC-28102 and Control DMEM/F12 Media
Cell Line Max Ig Concentration (μg/ml)
DMEM/F12 BTC-28102
2HG11 50 490 TBC3 84 1200 EXAMPLE 12 Preparation and Use of BTC-28103 to Culture CHO Cells This invention illustrates use of the invention to culture mammalian cells that express natural or recombinant protein. BTC-28103 was prepared as in BTC- 28101 but the buffer contents of HEPES and NaHCO were increased to 8330 mg/1 and 2650 mg/1, respectively. As a result, osmolarity of the medium was increased to 360 mOsm/Kg. CHO (Chinese Hamster Ovary) cells were adapted to grow in suspension and cultured in 100 ml of BTC-28103 and the control IMDM in shaker flasks, both supplied with 10% FBS, thymidine and hypoxanthine . Growth of the cultures was followed daily by hemocytometer counting and presented in Fig. 5. The media of the invention is useful to culture protein expressing cell lines in the various forms of available bioreactors. In particular, media of this invention may be used as the intracapillary medium in hollow fiber bioreactor culture of recombinant protein expressing CHO cells.
EXAMPLE 13 Table XIII indicates the composition of the commercially available media RPMI , D/F and eRDF and of the 28101 (Example 1) and 28102 (Example 11) media of the invention. Table XIII
Figure imgf000026_0001
The correlation of % amino acid content in medium with MAB production is presented in Fig. 6.
A novel cell culture media which improves protein production by cells of all types including mammalian cells which express recombinant protein vectors has been disclosed. The invention will substantially enhance the cost effectiveness of cell culture procedures generally including the production of monoclonal antibodies.
BIBLIOGRAPHY
(1) Murakami, H. (1989) Serum-free media used for cultivation of hybridomas. In: A. Mizrahi (Ed. ) , Advances in Biotechnological Processes, Vol. 11, Monoclonal Antibodies: Production and Application.
Alan R. Liss, New York, pp. 107-141.
(2) Chua, F., et al . (1994) Journal of Immunological Methods 167:109-119.
(3) Chua, F., et al . (1994) Journal of Biotechnology 37:265-275.
(4) Oh, S.K.W., et al. (1995) Biotechnology and Bioengineering 48 : 525-535.
(5) Oh, S.K.W., et al. (1996) "Flow Cytometric Studies of Osmotically Stressed and Sodium Butyrate-Treated Hybridoma Cells" in Flow Cytometry Applications in
Cell Culture, Marcel Dekker, Inc., (Eds. M. Al- Rubeai and A.N. Emery) New York, Basel, Hong Kong, pp. 101-119.

Claims

WHAT WE CLAIM:
1. In a cell culture medium comprising an aqueous solution of amino acids and a carbohydrate energy source for cells cultured in said medium, the improvement wherein said aqueous solution
(i) is substantially saturated with said amino acids at a temperature of 30┬░ to 50┬░C;
(ii) has an osmolarity of 320 to 450 mOsm; (iii) contains 5.50 to 20 grams per liter of amino acids and 5.50 to 15 grams per liter of said carbohydrate energy source and wherein the dry weight of the amino acids in solution in said medium comprises at least 20% of the total dry weight of all solid components present in said medium.
2. The claim 1 cell culture medium in which said carbohydrate energy source is glucose.
3. The claim 1 cell culture medium in which said osmolarity of from 320 to 450 mOsm is provided at least in part by sodium salt.
4. The claim 1 or claim 2 cell culture medium in which said osmolarity of from 320 to 450 mOsm is provided at least in part by a sodium chloride osmolyte .
5. The claim 1 cell culture medium further comprising a suspension of undissolved amino acids in said aqueous solution substantially saturated with amino acids wherein said substantial saturation is maintained as cell growth consumes amino acids in solution in said aqueous medium.
6. In an aqueous basal cell culture medium, the improvement which comprises providing in said basal medium
(i) a concentration of one or more amino acids reactive with cell transport system A to provide a total amino acid concentration of 5.50 to 20 grams per liter; (ii) an osmolarity of from 320 to 420 mOsm said osmolarity being provided by a sodium salt osmolyte .
7. The claim 6 cell culture medium in which the osmolyte (ii) is sodium chloride.
8. The claim 6 cell culture medium in which said one or more amino acids reactive with cell transport system A are zwitterionic amino acids.
9. The claim 6 cell culture medium in which said one or more amino acids reactive with cell transport system A are selected from the group consisting of alanine, glycine, histidine, methionine, proline and serine.
10. The claim 6 or claim 7 or claim 8 cell culture medium in which said basal cell culture medium is RPMI, DMEM, Ham's F12, RDF or eRDF.
11. The cell culture medium 28101, 28102 or 28103.
12. The method which comprises culturing a cell in the culture medium of claim 1, claim 2, or claim 3, or claim 11.
13. A method which comprises:
(i) providing the cell culture medium of claim 1 or claim 2 or claim 3 or claim 11;
(ii) culturing a CHO cell containing a recombinant expression vector in the medium provided in step (i) ; and
(iii) recovering the recombinant protein expressed by said CHO cell.
14. The claim 13 method in which the CHO cell containing a recombinant expression vector is a dicistronic DHFR intron expression vector.
15. A method which comprises culturing a CHO cell in culture medium 28103.
16. The method of claim 13 wherein said cell cultured in said culture medium is a hybridoma.
17. The method which comprises culturing a mammalian cell in the culture medium of claim 1, claim 2 or claim 3 or claim 11.
18. The method which comprises culturing a mammalian cell having an expression vector for a recombinant protein in a culture medium of claim 1, or claim 2 or claim 3 or claim 11.
19. The method which comprises culturing a CHO cell or a BHK cell or a COS cell or a Namaliva cell having expression vector for a recombinant protein in a culture medium of claim 1, claim 2, claim 3 or claim 11.
20. The method which comprises culturing a cell in the culture medium of claim 6 or claim 7 or claim 8 or claim 9.
21. The method which comprises culturing a mammalian cell in the culture medium of claim 7 or claim 8 or claim 9.
22. The method which comprises culturing a mammalian cell having an expression vector for a recombinant protein in a culture medium of claim 7 or claim 8 or claim 9.
23. The method which comprises culturing a CHO cell or a BHK cell or a COS cell or a Namaliva cell having expression vector for a recombinant protein in a culture medium of claim 7 or claim 8 or claim 9.
24. A dry mixture of cell culture medium components comprising amino acids, carbohydrates and vitamins, wherein said amino acids component comprises at least 20% of the dry weight of said mixture.
25. The claim 24 mixture wherein said amino acids component comprises from 30% to 50% of the dry weight of said mixture .
PCT/US1998/006800 1997-04-07 1998-04-07 Cell culture media for enhanced protein production WO1998045411A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP54212698A JP2002501374A (en) 1997-04-07 1998-04-07 Cell culture media for enhanced protein production
CA 2286323 CA2286323C (en) 1997-04-07 1998-04-07 Cell culture media for enhanced protein production
EP98915312A EP0973867A4 (en) 1997-04-07 1998-04-07 Cell culture media for enhanced protein production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/833,500 1997-04-07
US08/833,500 US20020012991A1 (en) 1997-04-07 1997-04-07 Cell culture media for enhanced protein production

Publications (1)

Publication Number Publication Date
WO1998045411A1 true WO1998045411A1 (en) 1998-10-15

Family

ID=25264584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/006800 WO1998045411A1 (en) 1997-04-07 1998-04-07 Cell culture media for enhanced protein production

Country Status (5)

Country Link
US (3) US20020012991A1 (en)
EP (1) EP0973867A4 (en)
JP (1) JP2002501374A (en)
CA (1) CA2286323C (en)
WO (1) WO1998045411A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1549678A2 (en) * 2002-09-30 2005-07-06 Pfizer Products Inc. Hybridomas producing high levels of human sequence antibody
EP1551988A2 (en) * 2002-07-19 2005-07-13 Morphotek Inc. Methods for generating enhanced antibody-producing cell lines with improved growth characteristics
WO2006026445A1 (en) * 2004-08-27 2006-03-09 Wyeth Research Ireland Limited Production of polypeptides
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US20140314779A1 (en) * 2013-03-15 2014-10-23 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
WO2016156476A1 (en) * 2015-04-01 2016-10-06 Boehringer Ingelheim International Gmbh Cell culture medium
EP2154244B1 (en) 2007-04-26 2017-04-12 Chugai Seiyaku Kabushiki Kaisha Cell culture method using amino acid-enriched medium
EP2563906B1 (en) 2010-04-26 2017-11-08 Novartis AG Process for cultivation of cho cells
US10927342B2 (en) 2015-08-04 2021-02-23 Regeneran Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US11292829B2 (en) 2011-07-01 2022-04-05 Amgen Inc. Mammalian cell culture

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482031B1 (en) * 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US10119117B2 (en) 2016-01-28 2018-11-06 Nanogen Pharmaceutical Biotechnology Co., Ltd Universal, glycosylation enhancer, completely chemically defined medium formulation
WO2018018613A1 (en) * 2016-07-29 2018-02-01 广东东阳光药业有限公司 Cell culture medium and culture method for increasing purity of antibody

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950547A (en) * 1974-08-26 1976-04-13 Syntex (U.S.A.) Inc. Dietary composition and methods of preparing
US4724206A (en) * 1984-02-13 1988-02-09 Damon Biotech, Inc. Protein production using hypertonic media
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5316938A (en) * 1990-10-17 1994-05-31 Burroughs Wellcome Co. Defined media for serum-free tissue culture

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950547A (en) * 1974-08-26 1976-04-13 Syntex (U.S.A.) Inc. Dietary composition and methods of preparing
US4724206A (en) * 1984-02-13 1988-02-09 Damon Biotech, Inc. Protein production using hypertonic media
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5316938A (en) * 1990-10-17 1994-05-31 Burroughs Wellcome Co. Defined media for serum-free tissue culture

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHUA F. K. F., YAP M. G. S., OH S. K. W.: "HYPER-STIMULATION OF MONOCLONAL ANTIBODY PRODUCTION BY HIGH OSMOLARITY STRESS IN ERDF MEDIUM.", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL, vol. 37., 1 January 1994 (1994-01-01), NL, pages 265 - 275., XP002914184, ISSN: 0168-1656, DOI: 10.1016/0168-1656(94)90133-3 *
MURAKAMI H.: "SERUM-FREE MEDIA USED FOR CULTIVATION OF HYBRIDOMAS.", MONOCLONAL ANTIBODIES: PRODUCTION AND APPLICATION, XX, XX, vol. 11., 1 January 1989 (1989-01-01), XX, pages 107 - 141., XP002914185 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551988A2 (en) * 2002-07-19 2005-07-13 Morphotek Inc. Methods for generating enhanced antibody-producing cell lines with improved growth characteristics
EP1551988A4 (en) * 2002-07-19 2007-11-14 Morphotek Inc Methods for generating enhanced antibody-producing cell lines with improved growth characteristics
EP1549678A4 (en) * 2002-09-30 2006-01-18 Pfizer Prod Inc Hybridomas producing high levels of human sequence antibody
EP1549678A2 (en) * 2002-09-30 2005-07-06 Pfizer Products Inc. Hybridomas producing high levels of human sequence antibody
WO2006026445A1 (en) * 2004-08-27 2006-03-09 Wyeth Research Ireland Limited Production of polypeptides
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
EP2357250A3 (en) * 2004-08-27 2014-07-02 Pfizer Ireland Pharmaceuticals Production of polypeptides
US11661579B2 (en) 2007-04-26 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Cell culture method using amino acid-enriched medium
EP2154244B1 (en) 2007-04-26 2017-04-12 Chugai Seiyaku Kabushiki Kaisha Cell culture method using amino acid-enriched medium
EP2563906B1 (en) 2010-04-26 2017-11-08 Novartis AG Process for cultivation of cho cells
US11827692B2 (en) 2011-07-01 2023-11-28 Amgen Inc. Mammalian cell culture
US11685772B2 (en) 2011-07-01 2023-06-27 Amgen Inc. Mammalian cell culture
US11292829B2 (en) 2011-07-01 2022-04-05 Amgen Inc. Mammalian cell culture
US11673941B2 (en) 2011-07-01 2023-06-13 Amgen Inc. Mammalian cell culture
US11634476B2 (en) 2011-07-01 2023-04-25 Amgen Inc. Mammalian cell culture
US10017732B2 (en) * 2013-03-15 2018-07-10 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US10131873B2 (en) 2013-03-15 2018-11-20 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
AU2014233393B2 (en) * 2013-03-15 2020-05-28 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US10676710B2 (en) 2013-03-15 2020-06-09 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US10829732B2 (en) 2013-03-15 2020-11-10 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US20140314779A1 (en) * 2013-03-15 2014-10-23 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US20180346881A1 (en) * 2015-04-01 2018-12-06 Boehringer Ingelheim International Gmbh Cell culture medium
US11505784B2 (en) 2015-04-01 2022-11-22 Boehringer Ingelheim International Gmbh Cell culture medium
AU2016239662B2 (en) * 2015-04-01 2021-12-16 Boehringer Ingelheim International Gmbh Cell culture medium
EP3736326A1 (en) * 2015-04-01 2020-11-11 Boehringer Ingelheim International GmbH Cell culture medium
CN107429227A (en) * 2015-04-01 2017-12-01 勃林格殷格翰国际公司 Cell culture medium
AU2021282392B2 (en) * 2015-04-01 2023-11-16 Boehringer Ingelheim International Gmbh Cell culture medium
WO2016156476A1 (en) * 2015-04-01 2016-10-06 Boehringer Ingelheim International Gmbh Cell culture medium
US11312936B2 (en) 2015-08-04 2022-04-26 Regeneron Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use
US10927342B2 (en) 2015-08-04 2021-02-23 Regeneran Pharmaceuticals, Inc. Taurine supplemented cell culture medium and methods of use

Also Published As

Publication number Publication date
EP0973867A1 (en) 2000-01-26
CA2286323A1 (en) 1998-10-15
EP0973867A4 (en) 2002-12-04
US20020012991A1 (en) 2002-01-31
CA2286323C (en) 2010-06-15
US7601535B1 (en) 2009-10-13
JP2002501374A (en) 2002-01-15
US20100093039A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
US20100093039A1 (en) Cell Culture Media for Enhanced Protein Production
US20230272336A1 (en) Cell culture method using amino acid-enriched medium
US10981974B2 (en) Cell culture media containing combinations of proteins
CN101048511B (en) Production of polypeptides
AU632065B2 (en) Cell culture medium for enhanced cell growth, culture longevity and product expression
KR101733834B1 (en) Cell culture medium comprising small peptides
CA2797356C (en) Improved cell culture medium
US7709229B2 (en) Serum-free cell culture medium for mammalian cells
CN101048512B (en) Production of anti-amyloid beta antibodies
CA2554238C (en) Use of a serum-free cell culture medium for the production of il-18bp in mammalian cells
EP1957630A2 (en) Improved production of glycoproteins using manganese
ZA200305909B (en) Efficient recovery of correctly refolded proteins.
WO2014110440A1 (en) Methods for improved production and recovery of recombinant proteins from eukaryotic cell cultures
EP0659880B1 (en) Medium for culturing animal cells or antibody-producing cells
NZ554131A (en) Serum-free cell culture medium for mammalian cells
IE913346A1 (en) Media for culture of insect cells
JPWO2020252082A5 (en)
KR20150131280A (en) Use of tricarboxylic acid (tca) intermediates to control ammonia generation in cell culture

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2286323

Country of ref document: CA

Ref country code: CA

Ref document number: 2286323

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 542126

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998915312

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998915312

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998915312

Country of ref document: EP